Fast Five Quiz: Type 2 Diabetes Mellitus Comorbidities

Romesh Khardori, MD, PhD


January 21, 2022

Both ADA and ESC guidelines recommend aspirin therapy for secondary prevention of CAD in patients with type 2 DM and a history of atherosclerotic cardiovascular disease. For decades, aspirin therapy has been recommended for primary prevention of CAD, but more recent studies have demonstrated lack of benefit as a primary preventive agent for patients at moderate risk. According to American College of Cardiology/American Heart Association guidelines, low-dose aspirin may be considered for primary prevention of ASCVD in certain adults aged 40-70 years who are at higher risk for ASCVD but not at increased bleeding risk. However, low-dose aspirin should not be administered on a routine basis for primary prevention of ASCVD among adults less than 70 years of age, or at any age among patients who are at increased bleeding risk.

Dietary modifications and glycemic control play an important role in reducing patients' risk for complications and comorbidities associated with type 2 DM, but these interventions alone are not sufficient to reduce CAD risk in this patient population.

Learn more about minimizing risk for CAD risk in patients with type 2 DM.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.